Release date: 2015-06-17

China has made progress in the study of Middle East Respiratory Syndrome (MERS) antibodies.

On June 15, Fudan University said that Chinese and American scientists have cooperated in the development of highly effective anti-MERS virus antibodies (m336). This antibody is currently one of the best treatments for MERS virus.

M336 has extremely strong virus neutralization activity, and its binding affinity constant with MERS virus reaches the level of “picomolar”: in vitro experiments show that the antibody has a neutralizing activity against MERS pseudovirus of 0.005 μg/ml, which is aimed at MERS. The neutralizing activity of the virus reached 0.07 μg/ml. The results were published in the journal Journal of Virology, a leading international virology journal.

Fudan University told 澎湃News () that recently, the school's medical molecular virology/Ministry of Health Key Laboratory Jiang Shibo team cooperated with the National Institute of Health Dr. Dimitrov team and successfully developed MERS. The virus has a highly inhibitory activity of a fully human monoclonal antibody (m336). Recently, the team also found that m336 antibody is effective in monkey models of marmosets and rabbits, and its activity far exceeds the serum of convalescent animals.

Dr. Dimitrov has successfully treated more than 10 Hendra-Nipah-infected patients in Australia using a full-human monoclonal antibody (m102.4) produced in his laboratory.

Academician Zhong Nanshan said in an interview with Huashang Daily that the research team of the Basic Medical College of Fudan University cooperated with the National Institutes of Health to jointly develop a super active human-neutral neutralizing antibody m336 against MERS coronavirus. The animal test is very effective. I hope to conduct clinical trials as soon as possible. When applied to the clinic, it is first necessary to go to the laboratory for testing, then for animal testing, and finally for human testing, with a longer cycle. The MERS virus has a high viral load in the body, and it is more effective to kill the virus by the antibody, which is much faster than developing the anti-MERS virus.

As of June 15, the number of confirmed patients in Korea's MERS increased to 150, and the number of deaths increased to 16. The first suspected case also occurred in Europe.

In fact, as early as the rapid outbreak of MERS in Korea, scientists from various countries have begun to develop the mechanism of MERS virus infection and anti-MERS drugs, and Chinese scholars are deeply involved. In 2012, Professor Jiang Shibo and his team focused on the development of the MERS virus. Previously, Professor Jiang Shibo's team has made some progress in anti-MERS drug development, and developed an internationally leading anti-MERS peptide inhibitor (HR2P-M2).

The results of animal experiments show that HR2P-M2 polypeptide can effectively protect animals from lethal doses of MERS-CoV challenge by nasal administration, and can significantly reduce the viral load in the lungs of infected animals. The research results were recently published in the journal Journal of Infectious Diseases, the leading journal of international infectious diseases.

Jiang Shibo believes that the combination of this peptide and m336 antibody will have a better synergistic effect. Therefore, in the case of emergency and consent of patients or close contacts, m336 antibody can be associated with the peptide inhibitor HR2P. -M2 is used together for the prevention and treatment of MERS virus infection to save the lives of patients. In view of the faster progress of HR2P-M2 polypeptide, in addition to the clinical trial of antibody m336 as soon as Academician Zhong Nanshan proposed, the clinical trial of HR2P-M2 peptide should be carried out as soon as possible.

In addition, Saudi Arabia, which was the first to have a confirmed case of MERS, is working with several international pharmaceutical companies to develop vaccines to get listed before the MERS season to reduce the incidence of high-risk areas in the Middle East. Several institutions, including Harvard University, are also developing drugs and vaccines for MERS.

Source: 澎湃

Collagen & Peptide

Collagen Peptide,Hydrolyzed Collagen,Collagen Supplement,Hydrolyzed Bovine Collagen

Ningbo Nutrition Food Technology Co.,ltd. , https://www.collagenworkshop.com